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Summary Objective: Chronic granulomatous disease (CGD) is a rare inherited dis-
order of NADPH oxidase in which phagocytes fail to generate reactive antimicrobial
oxidants. Invasive fungal infections are an important cause of morbidity and mortal-
ity in CGD patients, with Aspergillus spp. being the most frequent fungal pathogens.
We reviewed the reported cases of osteomyelitis in CGD patients due to Aspergillus
nidulans and compared them with those due to Aspergillus fumigatus.
Methods: Twenty-four cases of osteomyelitis due to Aspergillus spp. in 22 male CGD
patients were found in MEDLINE.
Results: Fourteen cases (58%) were due to Aspergillus nidulans and ten cases to
Aspergillus fumigatus. No other aspergilli were reported as causes of osteomyelitis.
Osteomyelitis due to Aspergillus nidulans was associated with pulmonary infection
and involved ‘small bones’ more frequently than Aspergillus fumigatus osteomyelitis
(p = 0.032). Half of the CGD patients with Aspergillus nidulans osteomyelitis died
compared with none of those with Aspergillus fumigatus osteomyelitis (p = 0.019).
In both Aspergillus nidulans and Aspergillus fumigatus cases, cure was achieved by
prompt antifungal treatment combined with surgery and immunotherapy.
Conclusion: Aspergillus nidulans causes osteomyelitis in CGD patients relatively fre-
quently compared with Aspergillus fumigatus andmay be accompanied by higher mor-
tality. This contrasts with the low frequency with which Aspergillus nidulans causes
osteomyelitis in patients with other types of immunodeﬁciency.
© 2003 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Introduction
Chronic granulomatous disease (CGD) is a geneti-
cally determined primary immunodeﬁciency disor-
der in which phagocytic cells are unable to destroy
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certain bacteria and fungi.1 The underlying defect
is an inability of the nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase complex of
phagocytes to generate reactive oxidants such as
superoxide anion, hydrogen peroxide and hydroxyl
radicals, which are key elements in host defence
against pathogens.2 The most common form of
the disease is due to an X-linked recessive defect
in glycoprotein 91phox (gp91phox). The other three
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forms are due to autosomal recessive defects in
other major components of the oxidase, p22-phox
deﬁcient (p22phox), p47-phox deﬁcient (p47phox)
and p67-phox deﬁcient (p67phox), each of which is
encoded on a different chromosome.2
Chronic granulomatous disease patients are vul-
nerable to organisms that are catalase positive and
thus destroy hydrogen peroxide. These organisms
include Staphylococcus spp., Serratia, Nocardia,
mycobacteria and Aspergillus spp.; Penicillium,
Paecilomyces, Acremonium, Rhizopus spp. and de-
matiaceous moulds are isolated less frequently.3
The lungs are the most common sites of infection.
In the US Registry of CGD patients, the major-
ity of them suffered from at least one episode of
pneumonia followed by subcutaneous or liver ab-
scesses, suppurative adenitis, osteomyelitis, bac-
teremia/fungemia, cellulitis and meningitis.4
Fungal osteomyelitis due to Aspergillus spp. is
infrequent in CGD patients. In particular, long
bone osteomyelitis due to Aspergillus spp. has
been rarely described.5 We recently treated a
16-year-old boy with CGD suffering from femoral
osteomyelitis due to Aspergillus nidulans with-
out pulmonary involvement, who had a favorable
outcome.6 From this case we proceeded to review
all the cases of osteomyelitis due to A. nidulans
in CGD patients recorded in the English literature
(MEDLINE) and to compare them with those due to
Aspergillus fumigatus.
Literature review and methods
The MEDLINE database was searched using the
keywords ‘osteomyelitis’, ‘chronic granulomatous
disease’ and ‘Aspergillus’. All the articles found
by this means were reviewed and a master Excel
database was constructed. The references cited
in the above articles were screened for additional
cases of osteomyelitis due to Aspergillus spp. in
CGD patients.
A deﬁnite diagnosis of Aspergillus osteomyelitis
required a positive culture of bone tissue obtained
by an invasive procedure such as needle aspiration
or biopsy. Infection of the chest wall was deﬁned as
extensive damage to both thoracic soft tissue and
ribs. A debridement was deﬁned as a ‘limited’ in-
tralesional procedure if no special efforts had been
undertaken preoperatively or at operation to de-
ﬁne the maximum extent of the lesion and if the
debridement had been performed through a limited
cortical window. The debridement was considered
an ‘extensive’ intralesional procedure if an attempt
had been undertaken to identify the full extent
of infection, preoperatively with three-dimensional
imaging and at operation with wide exposure, and
if all of the involved tissue was debrided until nor-
mal tissue was reached.6
The statistical program GraphPad Instat (Graph-
pad Inc., San Diego, CA) was used to compare the
cases due to A. nidulans with those due to A. fumi-
gatus. Statistical evaluation of differences in pro-
portions and calculation of odds ratio (OR) and 95%
conﬁdence interval (CI) were performed by Fisher’s
exact test. A two-sided P value of <0.05 indicated
statistical signiﬁcance.
Results
Twenty-four cases of osteomyelitis due to A. nidu-
lans and A. fumigatus in CGD patients have been
recorded in the MEDLINE database to date. Four-
teen cases were due to A. nidulans (58%) and ten
due to A. fumigatus. One patient had two bone in-
fections due to A. nidulans and another patient had
two bone infections due to A. fumigatus. In total,
13 patients with CGD suffered from osteomyelitis
due to A. nidulans (Table 1) and nine due to A. fu-
migatus (Table 2).
Demographics
The median age of the patients when the ﬁrst
episode of A. nidulans skeletal infection occurred
was 11 years ranging from four to 20 years. Simi-
larly, in cases of osteomyelitis due to A. fumigatus,
the median age at which the ﬁrst skeletal infection
was identiﬁed was ten years ranging from four to
19 years.
All CGD patients with osteomyelitis due to these
fungi were male. In all nine patients who suffered
from osteomyelitis due to A. nidulanswhose genetic
pattern was reported, it was X-linked inheritance.
On the other hand, among three patients suffering
from osteomyelitis due to A. fumigatus whose ge-
netic pattern was reported, it was X-linked gp91phox
in two and autosomal recessive form p67phox in one
(Table 3).
Sites of infection
The most frequently affected bones in cases of os-
teomyelitis due to A. nidulans in CGD patients were
vertebrae, followed by ribs and other chest wall
bones and soft tissue (Table 4). In 12 of the 14 cases
(86%), osteomyelitis of small bones resulted from
contiguous spread of pulmonary infection; only in
two of the 14 cases (14%), lungs were not involved.
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Table 1 Cases of osteomyelitis due to Aspergillus nidulans in patients with chronic granulomatous disease, sorted by year of diagnosis.
Patienta Reference Age
(yr)
Genotypeb Year of
publication
Site Antifungal therapy Adjunctive therapy Surgery Outcome
1 7 6 NA 1965 Ribs, vertebraec DAMB No Yes Died
2 8 8 gp91phox 1974 Ribc DAMB WBC transfusion No Survived
3 9 10 NA 1977 Ribs, vertebraec DAMB No Yes Survived
4 3 4 gp91phox 1998 (diagnosis
in 1986)
Chest wall,
vertebraec
DAMB + ﬂucytosine IFN- + WBC transfusion Yes Died
5 10 20 gp91phox 1989 Rib, femur,
skullc
DAMB + ﬂucytosine
+ itraconazole
No Yes Survived
6 5 4 X-linked 1991 Ribs, vertebraec DAMB WBC transfusion Extensive Died
7 5 9 gp91phox 1991 Ribc DAMB No Yes Survived
7 5 13 gp91phox 1991 Vertebraed DAMB No Extensive Survived
8 3 19 gp91phox 1998 (diagnosis
in 1992)
Chest wall,
vertebrae,
skullc
DAMB + LAMB + ﬂucytosine IFN- + WBC transfusion
+ local instillation of
granulocytes and hydrogen
peroxide
Yes Died
9 3 16 gp91phox 1998 (diagnosis
in 1993)
Chest wall,
vertebraec
DAMB + LAMB + itraconazole IFN- + WBC transfusion Yes Survived
10 11 19 gp91phox 1994 Chest wallc DAMB + LAMB + itraconazole
+ ﬂuconazole + rifampicin
+ ﬂucytosine
G-CSF + WBC transfusion No Died
11 3 7 gp91phox 1998 (diagnosis
in 1996)
Chest wall,
vertebraec
DAMB + LAMB + ﬂucytosine IFN- + WBC transfusion Yes Died
12 12 6 NA 1997 Chest wall,
vertebraec
DAMB + itraconazole GM-CSF + IFN- Yes Died
13 6 16 NA 2003 Left femurd LAMB + itraconazole IFN- + local instillation of
DAMB + G-CSF
Extensive Survived
NA: not available; gp91phox: glycoprotein 91phox; DAMB: deoxycholate amphotericin B; LAMB: liposomal amphotericin B; ABLC: amphotericin B lipid complex;
WBC: white blood cells; G-CSF: granulocyte colony stimulating factor; GM-CSF: granulocyte-macrophage colony stimulating factor; IFN-: interferon-; IFN-:
interferon-.
a All patients were male.
b gp91phox is the X-linked gene that encodes the 91Kd transmembrane protein of the NADPH oxidase complex, p67phox encodes the 67Kd cytosolic subunit of the
NADPH oxidase complex.
c Contiguous spread from a pulmonary infection.
d Bone infection without pulmonary infection.
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Table 2 Cases of osteomyelitis due to Aspergillus fumigatus in patients with chronic granulomatous disease, sorted by year of diagnosis.
Patienta Reference Age
(yr)
Genotypeb Year of
publication
Site Antifungal therapy Adjunctive
therapy
Surgery Outcome
1 13 6 NA 1983 Primary in left
femur,
secondary in
vertebraed
DAMB + ﬂucytosine No Limited Survived
2 14 4 NA 1987 Craniumd DAMB + ﬂucytosine No Extensive Survived
3 15 18 NA 1990 Ribs and left
humerusc
DAMB → itraconazole No No Survived
4 5 19 gp91phox 1991 Sternumc DAMB WBC transfusion Extensive Survived
5 16 15 NA 1991 Right
humerusd
DAMB + ﬂucytosine →
itraconazole p.o.
IFN- Extensive Survived
6 17 10 NA 1994 Right second
ribc
Itraconazole IFN- No Survived
6 17 11 NA 1994 1st, 2nd and
3rd thoracic
vertebraed
DAMB + itraconazole →
ABLC + itraconazole
IFN- + WBC
transfusion
No Survived
7 3 7 gp91phox 1998
(diagnosis in
1995)
Chest walld DAMB No Extensive Survived
8 18 10 NA 1996 Right femurc Itraconazole IFN- No Survived
9 19 9 p67phox 1999 Tibiad Fluconazole → DAMB–
—itraconazole p.o.
IFN- Extensive Survived
NA: not available; gp91phox: glycoprotein 91phox; DAMB: deoxycholate amphotericin B; ABLC: amphotericin B lipid complex; WBC: white blood cells; IFN-:
interferon-.
a All patients were male.
b gp91phox is the X-linked gene that encodes the 91Kd transmembrane protein of the NADPH oxidase complex, p67phox encodes the 67Kd cytosolic subunit of the
NADPH oxidase complex.
c Contiguous spread from a pulmonary infection.
d Bone infection without pulmonary infection.
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Table 3 Relationship between genetic subtypes of chronic granulomatous disease and osteomyelitis due to
Aspergillus spp.
Genetic subtype Aspergillus nidulans
(13 patients)
Aspergillus fumigatus
(9 patients)
Total (22
patients)
X linked CGDa 9 (8) 2 (2) 11
p67phox-deﬁcient None 1 1
Not reported 4 6 10
a gp91phox-deﬁcient pattern in parenthesis.
Two cases3,10 exhibited multifocal extension;
in one of them the affected bones were chest
wall, vertebrae and skull.3 Only two cases of
femoral osteomyelitis due to A. nidulans were
described.6,10 In the ﬁrst case,10 osteomyeli-
tis was part of a multifocal disseminated dis-
ease also involving the lungs (probably the portal
of entry) ribs, skull and femur. To our knowl-
edge, the second case6 was the only case of A.
nidulans long-bone osteomyelitis described in
a CGD patient without simultaneous pulmonary
infection.
By comparison, osteomyelitis due to A. fumi-
gatus showed no predilection for particular bones
(Table 4). Two multifocal osteomyelitis cases were
described.13,15 The bones most frequently involved
were ribs, vertebrae, humerus and femur. In four
of the ten published cases (40%), the bone infec-
tion was probably the result of contiguous spread
of pulmonary infection. In the remaining six cases,
the lungs were not involved. Osteomyelitis due to
A. nidulans was more frequently associated with
pulmonary infection (12 out of 14—86% of cases)
than that due to A. fumigatus (four out of ten–
—40% of cases; OR = 9.0, 95% CI 1.27 to 63.9,
p = 0.032).
Table 4 Site of osteomyelitis in cases due to As-
pergillus nidulans or Aspergillus fumigatus in patients
with chronic granulomatous disease.
Site Aspergillus
nidulans
(n = 14) (%)
Aspergillus
fumigatus
(n = 10) (%)
Vertebrae 9 (64) 2 (20)
Ribs 6 (43) 2 (20)
Chest wall 6 (43) 1 (10)
Femur 2 (14) 2 (20)
Humerus 0 2 (20)
Skull 2 (14) 1 (10)
Tibia 0 1 (10)
Sternum 0 1 (10)
Antifungal therapy
Amphotericin B was used in 22 of the 24 (92%)
cases of Aspergillus osteomyelitis (Table 5). In
all the cases of osteomyelitis due to A. nidulans,
amphotericin B was used as drug of ﬁrst choice.
In ﬁve of 14 cases (36%), the liposomal form of
the drug was used. For the treatment of A. fu-
migatus osteomyelitis, amphotericin B was used
in eight of ten cases (80%), and amphotericin B
lipid complex was utilized in only one case. In two
cases of A. fumigatus osteomyelitis, monotherapy
with itraconazole resulted in a favorable response.
Flucytosine was always used together with ampho-
tericin B. In one case, rifampicin was used together
with amphotericin B, itraconazole, ﬂucytosine and
ﬂuconazole11 and in another case local instillation
of deoxycholate amphotericin B was utilized.6
Immunotherapy
White blood cell (WBC) transfusions have been
suggested for the control of major infections in
patients with CGD.20 From a total of 24 cases,
WBC transfusions were administered in nine (38%)
of them (Table 5). In particular, WBC transfusions
were administered in seven of 14 cases (50%) of A.
nidulans bone infections and in two of ten cases
(20%) of A. fumigatus bone infections (p = 0.21).
The WBC transfusions were given three to ﬁve times
each week for up to three weeks. Interferon-
(IFN-) was also used in ten of 24 (42%) cases with
no difference between A. nidulans and A. fumiga-
tus cases. Although the numbers of patients were
small, there was no signiﬁcant difference in sur-
vival rate between IFN--treated and non-treated
patients with A. nidulans osteomyelitis.
In only three of 14 (21%) cases of A. nidulans
and in no case of A. fumigatus osteomyelitis,
granulocyte colony stimulating factor (G-CSF) or
granulocyte-macrophage colony stimulating fac-
tor (GM-CSF) were used. In persistent cases, other
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Table 5 Antifungal drug treatment and immunotherapy of osteomyelitis cases due to Aspergillus nidulans and
Aspergillus fumigatus in patients with chronic granulomatous disease.
Treatment Aspergillus nidulans
(n = 14)
Aspergillus
fumigatus (n = 10)
Amphotericin B 14 8
Deoxycholate amphotericin B 13 8
Liposomal amphotericin B 5 0
Lipid complex amphotericin B 0 1
Itraconazole 5 6
Flucytosine 5 3
Fluconazole 1 1
Rifampicin 1 0
Interferon- 5 5
Interferon- 1 0
Transfusion of white blood cells 7 2
Granulocyte colony stimulating factor 2 0
Granulocyte-macrophage colony stimulating factor 1 0
Local instillation of deoxycholate amphotericin B 1 0
Local instillation of granulocytes and hydrogen peroxide 1 0
Table 6 Relationship between surgery and mortality in cases of osteomyelitis due to Aspergillus nidulans and
Aspergillus fumigatus in patients with chronic granulomatous disease.
Aspergillus nidulans Aspergillus fumigatus P value
Number of cases 14 10
Mortality 7 (50%) 0 (0%) 0.019
Number of cases with surgery 12 6
Mortality with surgery 6 (50%) 0 (0%) 0.054
Number of cases without surgery 2 4
Mortality without surgery 1 (50%) 0 (0%)
adjunctive therapies such as interferon- (IFN-)
or local instillation of granulocytes and hydrogen
peroxide were used with varying results.
Surgery
Surgical debridement appears to have played a very
important role in the treatment of osteomyelitis
due to Aspergillus spp. In 18 of 24 cases (75%),
surgical debridement combined with antifungal
agents was used (Table 6). In the remaining six
cases (25%), treatment was attempted with anti-
fungal agents alone, but in one of the two cases of
A. nidulans infection it resulted in death. Because
some of the infections involved several compart-
ments, a true wide margin was usually impossible
and was obtained for only one infection. A limited
intralesional debridement appeared to be less ef-
fective than extensive debridement especially in
osteomyelitis cases due to A. nidulans.3,5
Outcome
The overall mortality of osteomyelitis in CGD pa-
tients was seven deaths in 24 cases (29%). However,
the mortality among patients with osteomyelitis
due to A. nidulans was 50% (seven deaths in 14
cases). By contrast, in patients with osteomyelitis
due to A. fumigatus there were no reported deaths
(no deaths in ten cases; OR = 21.0, 95% CI = 1.03
to 427.3, p = 0.019). This difference in mortal-
ity between A. nidulans and A. fumigatus cases
tended to be observed even after surgical ther-
apy (OR = 13.0, 95% CI 0.6 to 281.7, p = 0.054;
Table 6).
Discussion
This review of the reported cases of osteomyeli-
tis due to Aspergillus spp. in CGD patients suggests
that:
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1. A. nidulans causes osteomyelitis in these pa-
tients more frequently than A. fumigatus.
2. A. nidulans may affect ‘small bones’ in connec-
tion with lungs more frequently than A. fumiga-
tus does.
3. A. nidulans is associated with increased mortal-
ity compared with A. fumigatus.
Taking into account that this is a retrospective,
multi-source case review study, limitations imposed
by the data may affect the strength of conclusions
drawn from it.
A. fumigatus is by far the most common ﬁlamen-
tous fungus, causing 80—90% of cases of invasive
aspergillosis in immunocompromised patients21 and
is the most frequent cause of invasive aspergillosis
in CGD patients.4 However, A. nidulans was found
to be a more frequent cause of osteomyelitis in
CGD patients than A. fumigatus. Why this partic-
ular association of A. nidulans with skeletal infec-
tions exists in CGD patients is unclear. What is clear,
however, is that A. nidulans osteomyelitis in CGD
patients is frequently associatedwith pulmonary as-
pergillosis and with increased mortality compared
with A. fumigatus osteomyelitis.
Historically, the overall incidence of fungal infec-
tions has been reported to be 20% in CGD patients,
with Aspergillus spp. being responsible for 78% of
all fungal infections in these patients.22 More re-
cently, Aspergillus spp., especially A. fumigatus,
have become one of the predominant causes of in-
fections in CGD patients.4 Aspergillosis is the most
common cause of mortality in patients with CGD
and is responsible for over one third of deaths.
Osteomyelitis in CGD patients, most frequently re-
sulting from contiguous spread of a pulmonary in-
fection, has occurred in 25% of patients. Aspergillus
spp. are the second most common cause, account-
ing for approximately 22% of all osteomyelitis
cases.4
The most serious pattern of infectious involve-
ment in CGD patients was the spread of infection
from an abscess in the lung to the bones of the
thoracic wall and spine. Complete debridement of
the site of vertebral infection is extremely difﬁ-
cult anatomically, although the procedure can be
successful.5 Thus, the earlier a vertebral infection
is debrided, the more complete the debridement
can be and in cases in which it was performed, the
patients had an excellent response.
Patients with the X-linked recessive form of the
disease appear to have a more serious clinical phe-
notype than patients with the autosomal recessive
forms of the disease, based on the fact that they
are diagnosed signiﬁcantly earlier in the course of
the disease and they have a signiﬁcantly higher
prevalence of infections.3 In the 11 cases where the
patient had the X-linked recessive form (including
gp91phox-deﬁciency) of the disorder, a mortality of
45.5% (ﬁve of 11 cases) was observed.
Patients with A. nidulans osteomyelitis received
longer courses of amphotericin B therapy than pa-
tients with A. fumigatus osteomyelitis.3 Because
the literature on osteomyelitis due to the two As-
pergillus spp. in patients with CGD is limited to
case reports in which disparate therapies were
provided, it is difﬁcult to deﬁne the best treat-
ment of this devastating infection.3 Nevertheless,
in A. nidulans osteomyelitis early extensive surgery
appears to be important.
Hematopoietic growth factors may play an
important role in the treatment of invasive as-
pergillosis in patients with CGD.23 The use of
hematopoietic factors and T helper 1 cytokines in
aspergillosis6,12,16—19 seems to be effective. G-CSF
acts on polymorphonuclear leukocytes (PMNs), pro-
moting their maturation and increasing their num-
ber in peripheral blood, helping patients to clear
infections such as osteomyelitis due to A. nidulans.
On the other hand, GM-CSF may be more help-
ful as it acts on both granulocytic and monocytic
lineages, regulating not only the number of PMNs
but also of macrophages. The use of IFN- in pa-
tients with CGD as prevention and therapy may also
be helpful.24 In parallel with the use of antifun-
gal agents, improving immune response by either
exogenous modulation of enhancing/regulatory
cytokines or by transfusion of cytokine-elicited
allogeneic phagocytes appears to be a promising
adjunct to antifungal chemotherapy.
Conclusion
In conclusion, this study shows that osteomyelitis
due to A. nidulans may be more common in CGD
patients and more difﬁcult to control than that due
to A. fumigatus. Osteomyelitis due to A. nidulans
causes increased morbidity and mortality in CGD
patients and requires prompt medical and surgical
treatment.
Conﬂict of interest: No conﬂicting interest
declared.
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